Severe acute respiratory syndrome-coronavirus (SARS-CoV-2) is an emerging virus responsible for the pandemic Coronavirus Disease 2019 (COVID-19) declared as a “Public Health Emergency” by the World Health Organization. In most cases, clinical features of COVID-19 remain benign. Nevertheless, COVID-19 condition can be more severe with need for oxygen support at hospital in 16% of patients. Severe form of the disease is associated with severe pneumonia, and can deteriorate to critical form of the disease, with an acute respiratory distress syndrome (ARDS) in 5 to 10% of patients requiring invasive mechanical ventilation.
Lung injury observed during ARDS results from a massive dysregulated inflammatory response including recruitment and aggregation of immune cells, particularly neutrophils, into the lungs, lowering oxygen transfer to the blood and leading to hypoxia. ARDS induces acute and long term pulmonary and cardiovascular damages such as coagulopathy, micro-thrombosis and pulmonary fibrosis. ARDS is responsible for 99% of admission to Intensive Care Unit and COVID-19 related deaths.
Based on the outstanding research on ARDS performed by Pr. Patrick Berger at Bordeaux Hospital (France), we are developing a targeted therapeutic approach to improve respiratory function, using an EMA/FDA approved drug.
4P021 targets the mechanism of recruitment and aggregation of specific immune cells into the lungs, consequently, avoiding pulmonary and cardiac acute and chronic complications related to Covid-19.
The repositioning of 4P021 for the treatment of patients with severe COVID-19 is a collaborative effort of 4P-Pharma, Professor Patrick Berger‘s team at CHU Bordeaux, Bordeaux University, INSERM and the SATT Aquitaine.
This concerted action is a strong testimony of 4P-Pharma’s vision that public/private alliance is key to tackle the most pressing medical challenges such as COVID-19.
4P021 is now part of 4Living Biotech, a 4P-Pharma spin-off company dedicated to the clinical development of our COVID-19 treatment. 4Living Biotech was founded in August 2020.
Today, we are actively looking for funding to finance an international multicenter phase III clinical trial in humans to bring 4P021 to the patients as soon as possible.
Campus de l’Institut Pasteur de Lille 1 Rue du Professeur Calmette 59000 Lille, France
+33 9 50 72 97 68 …